JP2013507439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507439A5 JP2013507439A5 JP2012534245A JP2012534245A JP2013507439A5 JP 2013507439 A5 JP2013507439 A5 JP 2013507439A5 JP 2012534245 A JP2012534245 A JP 2012534245A JP 2012534245 A JP2012534245 A JP 2012534245A JP 2013507439 A5 JP2013507439 A5 JP 2013507439A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- formula
- acceptable salt
- compound
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 26
- 108010050904 Interferons Proteins 0.000 claims 12
- 102000014150 Interferons Human genes 0.000 claims 12
- 229940079322 interferon Drugs 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- FKRSSPOQAMALKA-XILBPPKJSA-N CC(C)C(C(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c2cnc(C(CCC3)N3C(C(C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)C(C(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2-c(cc2)ccc2-c2cnc(C(CCC3)N3C(C(C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O FKRSSPOQAMALKA-XILBPPKJSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25064809P | 2009-10-12 | 2009-10-12 | |
| US61/250,648 | 2009-10-12 | ||
| US12/899,840 US8415374B2 (en) | 2009-10-12 | 2010-10-07 | Combinations of hepatitis C virus inhibitors |
| US12/899,840 | 2010-10-07 | ||
| PCT/US2010/051898 WO2011046811A1 (en) | 2009-10-12 | 2010-10-08 | Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015156771A Division JP2016000747A (ja) | 2009-10-12 | 2015-08-07 | Ｃ型肝炎ウイルス阻害剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507439A JP2013507439A (ja) | 2013-03-04 |
| JP2013507439A5 true JP2013507439A5 (enExample) | 2013-11-07 |
| JP5992828B2 JP5992828B2 (ja) | 2016-09-14 |
Family
ID=43385735
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534245A Expired - Fee Related JP5992828B2 (ja) | 2009-10-12 | 2010-10-08 | Ｃ型肝炎ウイルス阻害剤の組み合わせ |
| JP2015156771A Pending JP2016000747A (ja) | 2009-10-12 | 2015-08-07 | Ｃ型肝炎ウイルス阻害剤の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015156771A Pending JP2016000747A (ja) | 2009-10-12 | 2015-08-07 | Ｃ型肝炎ウイルス阻害剤の組み合わせ |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8415374B2 (enExample) |
| EP (1) | EP2488192B1 (enExample) |
| JP (2) | JP5992828B2 (enExample) |
| KR (1) | KR101755058B1 (enExample) |
| CN (2) | CN102655873A (enExample) |
| AU (1) | AU2010307144B2 (enExample) |
| BR (1) | BR112012008533A8 (enExample) |
| CA (1) | CA2777560A1 (enExample) |
| CL (1) | CL2012000919A1 (enExample) |
| CO (1) | CO6430507A2 (enExample) |
| EA (1) | EA020527B1 (enExample) |
| IL (1) | IL219123A (enExample) |
| MX (1) | MX351910B (enExample) |
| NZ (1) | NZ599284A (enExample) |
| PE (2) | PE20121432A1 (enExample) |
| PH (1) | PH12012500571A1 (enExample) |
| WO (1) | WO2011046811A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| NZ619205A (en) | 2009-05-13 | 2015-04-24 | Gilead Pharmasset Llc | Antiviral compounds |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8415374B2 (en) * | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| MX2012008658A (es) | 2010-01-25 | 2012-12-05 | Enanta Pharm Inc | Inhibidores del virus de la hepatitis c. |
| US9127021B2 (en) | 2010-04-09 | 2015-09-08 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20120196794A1 (en) * | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
| EP2603080A4 (en) | 2010-08-12 | 2014-01-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA201490254A1 (ru) * | 2011-08-24 | 2014-07-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Комбинированное лечение гепатита с |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| DE202012012956U1 (de) * | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| EP2773342A4 (en) * | 2011-10-31 | 2015-08-26 | Merck Sharp & Dohme | COMPOSITIONS FOR THE TREATMENT OF VIRUS DISEASES |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| WO2013101550A1 (en) * | 2011-12-29 | 2013-07-04 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
| US9326973B2 (en) * | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| HRP20161694T1 (hr) | 2012-10-19 | 2017-03-10 | Bristol-Myers Squibb Company | 9-metil supstituirani heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4) diazaciklopentadecinil karbamat derivati kao ne-strukturalni 3 (ns3) proteazni inhibitori za liječenje infekcija virusom hepatitisa c |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UA118256C2 (uk) | 2013-01-31 | 2018-12-26 | Гіліад Фармассет Елелсі | Комбінований склад двох противірусних сполук |
| US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN105555266B (zh) * | 2013-07-17 | 2018-11-30 | 百时美施贵宝公司 | 用于治疗丙型肝炎病毒的包含三环十六碳六烯衍生物的组合产品 |
| US9775831B2 (en) * | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| KR20240012476A (ko) | 2021-05-21 | 2024-01-29 | 길리애드 사이언시즈, 인코포레이티드 | 지카 바이러스 저해제로서의 펜타사이클릭 유도체 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060199773A1 (en) | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| AU2003264038A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Combination pharmaceutical agents as inhibitors of hcv replication |
| US20100158862A1 (en) | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| CA2715839C (en) | 2008-02-13 | 2014-12-09 | Bristol-Myers Squibb Company | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
| US8415374B2 (en) * | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
-
2010
- 2010-10-07 US US12/899,840 patent/US8415374B2/en not_active Expired - Fee Related
- 2010-10-08 MX MX2012003835A patent/MX351910B/es active IP Right Grant
- 2010-10-08 CN CN201080056248XA patent/CN102655873A/zh active Pending
- 2010-10-08 CN CN201510922510.9A patent/CN105343868A/zh active Pending
- 2010-10-08 JP JP2012534245A patent/JP5992828B2/ja not_active Expired - Fee Related
- 2010-10-08 PE PE2012000459A patent/PE20121432A1/es not_active Application Discontinuation
- 2010-10-08 WO PCT/US2010/051898 patent/WO2011046811A1/en not_active Ceased
- 2010-10-08 EP EP10765917.9A patent/EP2488192B1/en not_active Not-in-force
- 2010-10-08 KR KR1020127012196A patent/KR101755058B1/ko not_active Expired - Fee Related
- 2010-10-08 BR BR112012008533A patent/BR112012008533A8/pt not_active Application Discontinuation
- 2010-10-08 AU AU2010307144A patent/AU2010307144B2/en not_active Ceased
- 2010-10-08 PE PE2016000808A patent/PE20160800A1/es not_active Application Discontinuation
- 2010-10-08 CA CA2777560A patent/CA2777560A1/en not_active Abandoned
- 2010-10-08 PH PH1/2012/500571A patent/PH12012500571A1/en unknown
- 2010-10-08 EA EA201270555A patent/EA020527B1/ru not_active IP Right Cessation
- 2010-10-08 NZ NZ599284A patent/NZ599284A/xx unknown
-
2012
- 2012-04-05 IL IL219123A patent/IL219123A/en active IP Right Grant
- 2012-04-11 CO CO12059496A patent/CO6430507A2/es active IP Right Grant
- 2012-04-11 CL CL2012000919A patent/CL2012000919A1/es unknown
-
2013
- 2013-03-11 US US13/792,898 patent/US20130259832A1/en not_active Abandoned
-
2015
- 2015-08-07 JP JP2015156771A patent/JP2016000747A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507439A5 (enExample) | ||
| JP2011528713A5 (enExample) | ||
| JP2013537905A5 (enExample) | ||
| JP2015512860A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| ME02321B (me) | Antivirusna jedinjenja | |
| JP2013509429A5 (enExample) | ||
| HRP20201575T1 (hr) | Kombinacija dva protuvirusna sredstva namijenjena liječenju hepatitisa c | |
| JP2013542247A5 (enExample) | ||
| RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с | |
| JP2012513479A5 (enExample) | ||
| JP2014504643A5 (enExample) | ||
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| HRP20150725T1 (hr) | Kondenzirani imidazolilimidazoli kao antivirusni spojevi | |
| JP2009535352A5 (enExample) | ||
| JP2015517528A5 (enExample) | ||
| JP2014530874A5 (enExample) | ||
| JP2011519364A5 (enExample) | ||
| JP2013521279A5 (enExample) | ||
| JP2007501251A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2016503800A5 (enExample) | ||
| JP2013514359A5 (enExample) | ||
| JP2012512907A5 (enExample) | ||
| JP2011527299A5 (enExample) |